- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18.09. | Roche to acquire 89bio in a deal worth up to US$3.5bn | ||
| 18.09. | James MacDonald appointed as CEO of Yellowstone Biosciences | ||
| 17.09. | VarmX and CSL to collaborate in research deal worth up to $2.1bn | ||
| 17.09. | Graphene Medical Animation launches | ||
| 16.09. | Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis | ||
| 16.09. | PMi Awards 2025 | ||
| 15.09. | Johnson & Johnson seeks first EMA approval for icotrokinra for plaque psoriasis | ||
| 12.09. | Lilly launches global Alzheimer's campaign with Julianne Moore | ||
| 12.09. | John Morikis joins Johnson & Johnson's board of directors | ||
| 11.09. | Novartis to acquire Tourmaline Bio in a deal worth $1.4bn | ||
| 11.09. | Resolution Therapeutics appoints Lucy Singah as CFO and Daniel Kennedy as CBO | ||
| 10.09. | Novo Nordisk to cuts 9,000 jobs in an effort to streamline its operations | ||
| 10.09. | Inizio appoints Ryan Quigley as new CEO | ||
| 09.09. | Lilly and Circle Pharma agree to collaborate on new oral macrocycle therapies | ||
| 09.09. | Emma Bush appointed as CNX Therapeutics' Vice President, Commercial | ||
| 08.09. | Invivyd working with FDA towards potential Biologics License Application for COVID-19 | ||
| 08.09. | Adam Raff appointed as Orbital Therapeutics' Senior Vice President, Clinical Development | ||
| 08.09. | Atlantic currents: the changing tide of health policy in the US and Europe | ||
| 05.09. | PhotoPharmics' new advisory board to guide launch of FDA Breakthrough device for Parkinson's | ||
| 05.09. | TRIMTECH Therapeutics establishes Scientific Advisory Board | ||
| 04.09. | Genentech starts construction on manufacturing facility in North Carolina, US | ||
| 04.09. | David Weinreich appointed as Merck KGaA's Global Head of R&D and CMO, Healthcare | ||
| 03.09. | UK's first new type of antibiotic for UTIs in nearly 30 years approved by MHRA | ||
| 03.09. | Zack Lentz appointed as Chief Commercial Officer at OPEN Health | ||
| 02.09. | EMA orphan drug designation given to ReAlta for graft-versus-host disease therapy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .